DIA, founded as the Drug Information Association, today announced the election of officers and directors to its Board of Directors for the 2020-2021 term. Members assumed their respective positions July 1.

The 2020-2021 DIA Board of Directors is as follows:

Executive Committee:

• Chair: Lingshi Tan, PhD, Chairman and CEO, dMed Global
• Chair-Elect: Judith Ng-Cashin, MD, most recently Chief Medical Officer, AOBiome Therapeutics
• Immediate Past Chair: Rebecca Vermeulen, RPh, VP, Patients and Society Strategy Lead Product Development Head, Customer Strategy, Patient Partnership and Health Equity for Global Medical Affairs, Roche
• Secretary/Treasurer: Michael Romano, CPA, Partner, Finance and Accounting Outsourcing, RSM US LLP
• Barbara Lopez Kunz, MS, President & Global Chief Executive, DIA

Directors: *New board member

• *Karin Van Baelen, Head of Global Regulatory Affairs, Janssen, Pharmaceutical Companies of Johnson and Johnson
• *Michael Devoy, MD, Chief Medical Officer & Executive VP Medical Affairs and Pharmacovigilance, Bayer
• Elizabeth Garner, PhD, Chief Medical Officer, ObsEva
• *Frank Jiang, CEO, CStone Pharmaceuticals (Observer)
• Tatyana Kosheleva, CPA, MBA, Chief Financial Officer, Amring Pharmaceuticals Inc.
• Michael Rosenblatt, MD, Chief Medical Officer, Flagship Pioneering
• Peter Sorger, PhD, Otto Krayer Professor of Systems Biology and Head of the Harvard Program in Therapeutic Sciences – HiTS, Harvard Medical School
• Kihito Takahashi, MD, PhD, Vice President and Director, Development and Medical Affairs Division, GlaxoSmithKline K.K
• Cynthia Verst, PharmD, MS, President, Design and Delivery Innovation, IQVIA

“I’m very pleased to welcome Karin Van Baelen and Michael Devoy to the DIA Board of Directors, and Frank Jiang as our Observer. I’m also very happy to announce that on our Executive Committee, Lingshi Tan will serve as Chair, and Judith Ng-Cashin has been named Chair-Elect,” said Barbara Lopez Kunz, Global Chief Executive, DIA. “I know that we will be well-served by such a diverse, experienced, talented roster of thought leaders. The members of our Board are dedicated to the transformative nature of science, of course, but also adaptation of learning and knowledge-sharing in the context of global change. We lean heavily on the power of collaboration as we continue to deliver on our mission to accelerate the delivery of therapies to patients worldwide.”